Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2020 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Kymera Therapeutics, Inc. | 8 | Q3 2023 | 40.1% |
Day One Biopharmaceuticals, Inc. | 8 | Q3 2023 | 26.8% |
Dyne Therapeutics, Inc. | 8 | Q3 2023 | 15.4% |
Replimune Group, Inc. | 8 | Q3 2023 | 9.4% |
Generation Bio, Co. | 8 | Q3 2023 | 9.1% |
Aerovate Therapeutics, Inc. | 8 | Q3 2023 | 7.2% |
Akero Therapeutics, Inc. | 8 | Q3 2023 | 4.3% |
Ikena Oncology, Inc. | 8 | Q3 2023 | 5.8% |
Xilio Therapeutics, Inc. | 8 | Q3 2023 | 4.1% |
AVROBIO INC | 8 | Q3 2023 | 1.6% |
View Atlas Venture Life Science Advisors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-06 |
13F-HR | 2024-02-09 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-09 |
13F-HR | 2022-08-03 |
13F-HR | 2022-05-16 |
13F-HR | 2022-05-16 |
View Atlas Venture Life Science Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.